Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

December 5, 2018

Study Completion Date

December 6, 2018

Conditions

Healthy Volunteer

Interventions

DRUG

ORM-12741

Novel selective alpha2c adrenoceptor antagonist

DRUG

Placebo

Identical in appearance to experimental drug, not psycho-active

Trial Locations (1)

UCT Dept. Psychiatry & Mental Health / CUBIC, Cape Town

All Listed Sponsors

collaborator

Orion Corporation, Orion Pharma

INDUSTRY

collaborator

University of Oxford

OTHER

lead

University of Cape Town

OTHER

NCT03440021 - Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter